Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrakis Therapeutics Inc.

http://arrakistx.com

Latest From Arrakis Therapeutics Inc.

Venture Funding Deals: CNS Plays Are Attracting Investment

Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals... 

Financing StartUps and SMEs

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.
Financing StartUps and SMEs

Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies

Canaan Partners-backed biotech will investigate the therapeutic potential of three-way junctions in folded RNA. UC Berkeley and Duke sign separate license agreements related to CRISPR gene-editing technology.

Deals Platform Technologies

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Obsidian CEO Michael Gilman described the company's technology – which allows CAR-T cells and other therapies to be activated by available small molecule drugs – as being able to modulate the effective yet toxic therapies by dialing down, turning up or shutting off the treatments as needed.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Bioinformatics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Arrakis Therapeutics Inc.
  • Senior Management
  • Michael Gilman, PhD, CEO
    Jennifer C Petter, PhD, CSO
    Daniel E Koerwer , CBO
  • Contact Info
  • Arrakis Therapeutics Inc.
    830 Winter St.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register